Q Therapeutics, Inc. CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa
Published: Oct 09, 2013
SALT LAKE CITY, UT--(Marketwired - October 08, 2013) - Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that Deborah Eppstein, PhD, President and CEO, is scheduled to present at the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa.
The 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.
EVENT AT A GLANCE:
October 14, 2013
11:45 AM PT
Estancia La Jolla Hotel & Spa
La Jolla Ballroom AB
9700 North Torrey Pines Road
La Jolla, California
To learn more or to register for the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa, please visit www.stemcellmeetingonthemesa.com. Registration is required.
About Q Therapeutics, Inc.
Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2014. For more information, visit www.qthera.com.
FOR MORE INFORMATION:
Chief Operating Officer
Help employers find you! Check out all the jobs and post your resume.